Acuta Capital Partners, LLC Iveric Bio, Inc. Transaction History

Acuta Capital Partners, LLC

$98.8 Million
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $3.91 Million - $5.91 Million	-149,046 Reduced 53.14%	131,454 $5.17 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $1.49 Million - $1.96 Million	-80,000 Reduced 22.19%	280,500 $6.82 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $3.5 Million - $4.86 Million	-203,107 Reduced 36.04%	360,500 $7.72 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $219,855 - $455,622	24,107 Added 4.47%	563,607 $5.42 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $844,425 - $1.17 Million	69,500 Added 14.79%	539,500 $9.08 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $9.2 Million - $12.5 Million	-665,000 Reduced 58.59%	470,000 $7.86 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $813,050 - $2.01 Million	-115,000 Reduced 9.2%	1,135,000 $18.4 Million
Q2 2021 Aug 16, 2021	SELL	$5.69 - $7.17 $1.87 Million - $2.36 Million	-329,093 Reduced 20.84%	1,250,000 $7.89 Million
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $1.86 Million - $2.53 Million	366,593 Added 30.23%	1,579,093 $9.76 Million
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $2.32 Million - $3.14 Million	410,000 Added 51.09%	1,212,500 $8.38 Million
Q3 2020 Nov 16, 2020	BUY	$4.01 - $6.29 $461,150 - $723,350	115,000 Added 16.73%	802,500 $4.53 Million
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $1.68 Million - $3.62 Million	548,500 Added 394.6%	687,500 $3.51 Million
Q1 2020 May 15, 2020	SELL	$2.83 - $8.44 $2.18 Million - $6.51 Million	-771,000 Reduced 84.73%	139,000 $478,000
Q4 2019 Feb 14, 2020	BUY	$0.93 - $8.58 $846,300 - $7.81 Million	910,000 New	910,000 $7.81 Million

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.

Account